Selected article for: "cancer risk and mortality rate"
Author: Cai, Guangyao; Gao, Yue; Zeng, Shaoqing; Yu, Yang; Liu, Xingyu; Liu, Dan; Wang, Ya; Yu, Ruidi; Desai, Aakash; Li, Chunrui; Gao, Qinglei
Title: Immunological alternation in COVID-19 patients with cancer and its implications on mortality
  • Cord-id: ov4oedoq
  • Document date: 2021_1_4
    • ID: ov4oedoq
    Snippet: Patients with malignancy were reportedly more susceptible and vulnerable to Coronavirus Disease 2019 (COVID-19), and witnessed a greater mortality risk in COVID-19 infection than noncancerous patients. But the role of immune dysregulation of malignant patients on poor prognosis of COVID-19 has remained insufficiently investigated. Here we conducted a retrospective cohort study that included 2,052 patients hospitalized with COVID-19 (Cancer, n = 93; Non-cancer, n = 1,959), and compared the immuno
    Document: Patients with malignancy were reportedly more susceptible and vulnerable to Coronavirus Disease 2019 (COVID-19), and witnessed a greater mortality risk in COVID-19 infection than noncancerous patients. But the role of immune dysregulation of malignant patients on poor prognosis of COVID-19 has remained insufficiently investigated. Here we conducted a retrospective cohort study that included 2,052 patients hospitalized with COVID-19 (Cancer, n = 93; Non-cancer, n = 1,959), and compared the immunological characteristics of both cohorts. We used stratification analysis, multivariate regressions, and propensity-score matching to evaluate the effect of immunological indices. In result, COVID-19 patients with cancer had ongoing and significantly elevated inflammatory factors and cytokines (high-sensitivity C-reactive protein, procalcitonin, interleukin (IL)-2 receptor, IL-6, IL-8), as well as decreased immune cells (CD8 + T cells, CD4 + T cells, B cells, NK cells, Th and Ts cells) than those without cancer. The mortality rate was significantly higher in cancer cohort (24.7%) than non-cancer cohort (10.8%). By stratification analysis, COVID-19 patients with immune dysregulation had poorer prognosis than those with the relatively normal immune system both in cancer and non-cancer cohort. By logistic regression, Cox regression, and propensity-score matching, we found that prior to adjustment for immunological indices, cancer history was associated with an increased mortality risk of COVID-19 (p < .05); after adjustment for immunological indices, cancer history was no longer an independent risk factor for poor prognosis of COVID-19 (p > .30). In conclusion, COVID-19 patients with cancer had more severely dysregulated immune responses than noncancerous patients, which might account for their poorer prognosis. Clinical Trial: This study has been registered on the Chinese Clinical Trial Registry (No. ChiCTR2000032161).

    Search related documents:
    Co phrase search for related documents
    • adaptive immune response and lung cancer: 1
    • adaptive innate and additional insight: 1
    • adaptive innate and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8
    • adaptive innate and lung cancer: 1, 2, 3, 4, 5, 6, 7
    • adaptive innate immune response and logistic regression: 1, 2, 3
    • adaptive innate immune response and lung cancer: 1
    • additional insight and logistic regression: 1
    • logistic regression and longitudinal assessment: 1, 2, 3, 4, 5
    • logistic regression and low remain: 1, 2
    • logistic regression and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52
    • logistic regression and lymphocyte pct: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • logistic regression and lymphocyte procalcitonin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
    • logistic regression and lymphocyte procalcitonin count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • logistic regression model and longitudinal assessment: 1
    • logistic regression model and lung cancer: 1, 2, 3, 4, 5, 6
    • logistic regression model and lymphocyte pct: 1, 2, 3
    • logistic regression model and lymphocyte procalcitonin: 1, 2
    • low remain and lung cancer: 1, 2, 3